Will be heading off for a while for travel, but working through financials, and checking for updates in operations/plans/progress.
Questions:
Looking at updates to operations in the Chinese partnership from recent financials.
My approach is to compare yoy data to see how management has executed or not.
Main o principle is to use facts to guide me…
In summary:
7 years since the YuTian Chinese partnership and licence announced.
Almost 2 1/2 years since sales announced and “Additional sales are in progress and will be announced
as they are completed over the coming months” was a statement from fall of 2020.
Comparing the moist recent annual finacials and MRQ, previously, I see no update to managements guidance in progress and no reports of sales in the last year, despite hearing it would be months to report these completed sales.
Clearly this is stalled from what was stated.
To me, the follow-up in this area is devoid of important details.
Irrespective at this point, ny assessment is that execution in China has been stalled at best.
See below for relevant excepts from recent year end finacials and 2020 fro comparisons.
MDA sep 30th, 2020
Chinese Partnership and Future Development
The Company previously announced (see NR Nov 3, 2015) it had granted an exclusive license to develop
and manufacture knowledge-based reconstruction (“KBR”) products in the People’s Republic of China to
YuTian Medical Investment based in Shanghai and Yutian Technology located in Ma'anshan. (“Yutian”).
Yutian has developed a series of products to specifically meet the demands of the Chinese market based
on the KBR technology and has received regulatory approval for the sale of the KBR-based products in
China. Billing codes for RV Ultrasound Quantitative Analysis were granted in November of 2019 and the
first two sales in China closed in December of 2019. Additional sales are in progress and will be announced
as they are completed over the coming months
Update Dec 31,2021 MD&A
Chinese Partnership and Future Development
On February 16, 2021, the Company announced that its joint-venture partner Yutian Medical Shanghai Inc.
("Yutian") had informed the Company that it had achieved a number of milestones in its platform
development to commercialization.
Source:Sedar.com